Chris Shibutani's Stock Ratings

Goldman Sachs Analyst

Chris Shibutani is an analyst at Goldman Sachs. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 04/15/2025

Overall Average Return

-0.84%

Smart Score

55%

Overall Average Return Percentile

40th

Number of Ratings

116
Buy NowGet Alert
04/01/2025PCVXBuy Now
Vaxcyte
$32.04212.11%
Chris Shibutani54%
$138 → $100MaintainsBuyGet Alert
03/21/2025ERASBuy Now
Erasca
$1.22145.9%
Chris Shibutani54%
$3.5 → $3MaintainsBuyGet Alert
03/14/2025MCRBBuy Now
Seres Therapeutics
$0.5829.89%
Chris Shibutani54%
$1 → $0.75MaintainsSellGet Alert
02/14/2025ALKSBuy Now
Alkermes
$27.5416.19%
Chris Shibutani54%
$30 → $32MaintainsBuyGet Alert
12/20/2024PCVXBuy Now
Vaxcyte
$32.04321.35%
Chris Shibutani54%
→ $135Initiates → BuyGet Alert
11/08/2024BNTXBuy Now
BioNTech
$102.3433.87%
Chris Shibutani54%
$90 → $137UpgradeNeutral → BuyGet Alert
11/07/2024SNDXBuy Now
Syndax Pharmaceuticals
$11.24193.59%
Chris Shibutani54%
$30 → $33MaintainsBuyGet Alert
11/01/2024UTHRBuy Now
United Therapeutics
$284.316.22%
Chris Shibutani54%
$243 → $302MaintainsNeutralGet Alert
10/25/2024ALKSBuy Now
Alkermes
$27.548.93%
Chris Shibutani54%
$32 → $30MaintainsBuyGet Alert
10/25/2024ERASBuy Now
Erasca
$1.22186.89%
Chris Shibutani54%
$3 → $3.5MaintainsBuyGet Alert
08/14/2024ERASBuy Now
Erasca
$1.22145.9%
Chris Shibutani54%
$4 → $3MaintainsBuyGet Alert
08/14/2024RPRXBuy Now
Royalty Pharma
$31.5061.9%
Chris Shibutani54%
$50 → $51MaintainsBuyGet Alert
07/19/2024JNJBuy Now
Johnson & Johnson
$153.790.79%
Chris Shibutani54%
$160 → $155MaintainsNeutralGet Alert
07/12/2024AMLXBuy Now
Amylyx Pharma
$4.10-2.44%
Chris Shibutani54%
$3 → $4MaintainsNeutralGet Alert
05/28/2024ERASBuy Now
Erasca
$1.22227.87%
Chris Shibutani54%
$7 → $4MaintainsBuyGet Alert
05/13/2024RVNCBuy Now
Revance Therapeutics
——
Chris Shibutani54%
$9 → $8MaintainsNeutralGet Alert
05/06/2024OGNBuy Now
Organon
$11.3775.9%
Chris Shibutani54%
$18 → $20MaintainsNeutralGet Alert
05/03/2024UTHRBuy Now
United Therapeutics
$284.31-15.59%
Chris Shibutani54%
$218 → $240MaintainsNeutralGet Alert
05/03/2024OGNBuy Now
Organon
$11.3775.9%
Chris Shibutani54%
$18 → $20MaintainsNeutralGet Alert
04/11/2024LLYBuy Now
Eli Lilly and Co
$752.00-3.86%
Chris Shibutani54%
$650 → $723MaintainsNeutralGet Alert
04/02/2024ERASBuy Now
Erasca
$1.22473.77%
Chris Shibutani54%
$6 → $7MaintainsBuyGet Alert
03/11/2024AMLXBuy Now
Amylyx Pharma
$4.10-2.44%
Chris Shibutani54%
$40 → $4DowngradeBuy → NeutralGet Alert
03/01/2024SDGRBuy Now
Schrodinger
$26.54-2.03%
Chris Shibutani54%
$29 → $26MaintainsNeutralGet Alert
03/01/2024RVNCBuy Now
Revance Therapeutics
——
Chris Shibutani54%
$8 → $9MaintainsNeutralGet Alert
02/28/2024BNTXBuy Now
BioNTech
$102.34-2.29%
Chris Shibutani54%
$113 → $100MaintainsNeutralGet Alert
02/20/2024RPRXBuy Now
Royalty Pharma
$31.5058.73%
Chris Shibutani54%
$56 → $50MaintainsBuyGet Alert
02/20/2024OGNBuy Now
Organon
$11.3758.31%
Chris Shibutani54%
$16 → $18MaintainsNeutralGet Alert
02/12/2024UTHRBuy Now
United Therapeutics
$284.31-24.38%
Chris Shibutani54%
$213 → $215UpgradeSell → NeutralGet Alert
01/25/2024NBIXBuy Now
Neurocrine Biosciences
$94.3962.09%
Chris Shibutani54%
$134 → $153MaintainsBuyGet Alert
01/09/2024RVNCBuy Now
Revance Therapeutics
——
Chris Shibutani54%
$30 → $8DowngradeBuy → NeutralGet Alert
12/11/2023ABBVBuy Now
AbbVie
$178.50-3.08%
Chris Shibutani54%
→ $173UpgradeNeutral → BuyGet Alert
11/10/2023AMLXBuy Now
Amylyx Pharma
$4.10875.61%
Chris Shibutani54%
$46 → $40MaintainsBuyGet Alert
11/09/2023NKTRBuy Now
Nektar Therapeutics
$0.60—
Chris Shibutani54%
—UpgradeMarket Perform → OutperformGet Alert
11/03/2023MCRBBuy Now
Seres Therapeutics
$0.58116.49%
Chris Shibutani54%
$4 → $1.25MaintainsSellGet Alert
11/03/2023OGNBuy Now
Organon
$11.3740.72%
Chris Shibutani54%
$33 → $16DowngradeBuy → NeutralGet Alert
10/30/2023BMYBuy Now
Bristol-Myers Squibb
$51.4834.03%
Chris Shibutani54%
$81 → $69MaintainsBuyGet Alert
10/11/2023SNDXBuy Now
Syndax Pharmaceuticals
$11.24166.9%
Chris Shibutani54%
→ $30Initiates → BuyGet Alert
09/21/2023RVNCBuy Now
Revance Therapeutics
——
Chris Shibutani54%
$38 → $33MaintainsBuyGet Alert
08/10/2023LLYBuy Now
Eli Lilly
$752.00-37.5%
Chris Shibutani54%
$385 → $470MaintainsNeutralGet Alert
08/09/2023LLYBuy Now
Eli Lilly
$752.00-37.5%
Chris Shibutani54%
$385 → $470MaintainsNeutralGet Alert
07/24/2023AMLXBuy Now
Amylyx Pharma
$4.101095.12%
Chris Shibutani54%
$45 → $49UpgradeNeutral → BuyGet Alert
05/16/2023ERASBuy Now
Erasca
$1.22637.7%
Chris Shibutani54%
$10 → $9MaintainsBuyGet Alert
05/10/2023EQRXBuy Now
EQRx
——
Chris Shibutani54%
$5 → $3MaintainsNeutralGet Alert
03/28/2023BNTXBuy Now
BioNTech
$102.3436.8%
Chris Shibutani54%
$156 → $140MaintainsNeutralGet Alert
03/14/2023AMLXBuy Now
Amylyx Pharma
$4.101046.34%
Chris Shibutani54%
$41 → $47MaintainsNeutralGet Alert
03/03/2023INVABuy Now
Innoviva
$17.98-27.7%
Chris Shibutani54%
$15 → $13MaintainsNeutralGet Alert
03/01/2023RVMDBuy Now
Revolution Medicines
$38.29-39.93%
Chris Shibutani54%
$20 → $23MaintainsNeutralGet Alert
02/27/2023NKTRBuy Now
Nektar Therapeutics
$0.60230.58%
Chris Shibutani54%
$3 → $2MaintainsSellGet Alert
02/24/2023ERASBuy Now
Erasca
$1.22719.67%
Chris Shibutani54%
→ $10Initiates → BuyGet Alert
01/31/2023RXDXBuy Now
Prometheus Biosciences
——
Chris Shibutani54%
$117 → $144MaintainsBuyGet Alert
01/31/2023BNTXBuy Now
BioNTech
$102.3452.43%
Chris Shibutani54%
$177 → $156MaintainsNeutralGet Alert
12/19/2022VTYXBuy Now
Ventyx Biosciences
$1.084529.63%
Chris Shibutani54%
→ $50Initiates → BuyGet Alert
12/16/2022KYMRBuy Now
Kymera Therapeutics
$25.30105.53%
Chris Shibutani54%
$40 → $52MaintainsBuyGet Alert
12/13/2022PFEBuy Now
Pfizer
$22.18170.51%
Chris Shibutani54%
$47 → $60UpgradeNeutral → BuyGet Alert
12/05/2022UTHRBuy Now
United Therapeutics
$284.31-19.1%
Chris Shibutani54%
→ $230Initiates → SellGet Alert
11/11/2022EQRXBuy Now
EQRx
——
Chris Shibutani54%
$8 → $5DowngradeBuy → NeutralGet Alert
11/08/2022TRDABuy Now
Entrada Therapeutics
$7.10153.52%
Chris Shibutani54%
$13 → $18MaintainsNeutralGet Alert
11/08/2022LLYBuy Now
Eli Lilly
$752.00-58.38%
Chris Shibutani54%
$281 → $313MaintainsNeutralGet Alert
11/08/2022BNTXBuy Now
BioNTech
$102.3472.95%
Chris Shibutani54%
$200 → $177MaintainsNeutralGet Alert
09/22/2022RVNCBuy Now
Revance Therapeutics
——
Chris Shibutani54%
→ $33Initiates → BuyGet Alert
09/09/2022AMLXBuy Now
Amylyx Pharma
$4.10875.61%
Chris Shibutani54%
$22 → $40MaintainsNeutralGet Alert
08/16/2022TRDABuy Now
Entrada Therapeutics
$7.1083.1%
Chris Shibutani54%
$10 → $13MaintainsNeutralGet Alert
08/03/2022KYMRBuy Now
Kymera Therapeutics
$25.3058.1%
Chris Shibutani54%
→ $40Initiates → BuyGet Alert
07/20/2022INVABuy Now
Innoviva
$17.98-11.01%
Chris Shibutani54%
→ $16Initiates → NeutralGet Alert
07/20/2022RXDXBuy Now
Prometheus Biosciences
——
Chris Shibutani54%
→ $51Initiates → BuyGet Alert
06/13/2022EQRXBuy Now
EQRx
——
Chris Shibutani54%
→ $8Initiates → BuyGet Alert
05/24/2022EXAIBuy Now
Exscientia
——
Chris Shibutani54%
$23 → $20MaintainsBuyGet Alert
05/24/2022TRDABuy Now
Entrada Therapeutics
$7.1040.85%
Chris Shibutani54%
$22 → $10MaintainsNeutralGet Alert
05/24/2022BNTXBuy Now
BioNTech
$102.34101.29%
Chris Shibutani54%
$255 → $206MaintainsNeutralGet Alert
04/27/2022OGNBuy Now
Organon
$11.37251.8%
Chris Shibutani54%
→ $40Initiates → BuyGet Alert
04/27/2022RPRXBuy Now
Royalty Pharma
$31.5077.78%
Chris Shibutani54%
→ $56Initiates → BuyGet Alert
04/20/2022ALKSBuy Now
Alkermes
$27.5427.09%
Chris Shibutani54%
→ $35Initiates → BuyGet Alert
04/18/2022NKTRBuy Now
Nektar Therapeutics
$0.60395.87%
Chris Shibutani54%
→ $3DowngradeNeutral → SellGet Alert
04/12/2022JNJBuy Now
Johnson & Johnson
$153.7917.69%
Chris Shibutani54%
$163 → $181MaintainsNeutralGet Alert
04/12/2022LLYBuy Now
Eli Lilly
$752.00-64.89%
Chris Shibutani54%
$234 → $264MaintainsNeutralGet Alert
04/12/2022ABBVBuy Now
AbbVie
$178.50-21.57%
Chris Shibutani54%
$122 → $140MaintainsNeutralGet Alert
04/01/2022AMLXBuy Now
Amylyx Pharma
$4.10143.9%
Chris Shibutani54%
$36 → $10DowngradeBuy → NeutralGet Alert
02/25/2022NBIXBuy Now
Neurocrine Biosciences
$94.3921.83%
Chris Shibutani54%
→ $115UpgradeNeutral → BuyGet Alert
02/03/2022ABBVBuy Now
AbbVie
$178.50-31.65%
Chris Shibutani54%
$117 → $122MaintainsNeutralGet Alert
02/01/2022AMLXBuy Now
Amylyx Pharma
$4.10778.05%
Chris Shibutani54%
→ $36Initiates → BuyGet Alert
12/17/2021ABBVBuy Now
AbbVie
$178.50-36.69%
Chris Shibutani54%
→ $113Initiates → NeutralGet Alert
12/17/2021PFEBuy Now
Pfizer
$22.18129.94%
Chris Shibutani54%
→ $51Initiates → NeutralGet Alert
12/17/2021JNJBuy Now
Johnson & Johnson
$153.794.69%
Chris Shibutani54%
→ $161Initiates → NeutralGet Alert
12/17/2021LLYBuy Now
Eli Lilly
$752.00-68.62%
Chris Shibutani54%
→ $236Initiates → NeutralGet Alert
12/17/2021BMYBuy Now
Bristol-Myers Squibb
$51.4839.86%
Chris Shibutani54%
→ $72Initiates → BuyGet Alert
11/23/2021TRDABuy Now
Entrada Therapeutics
$7.10308.45%
Chris Shibutani54%
→ $29Initiates → NeutralGet Alert
10/26/2021EXAIBuy Now
Exscientia
——
Chris Shibutani54%
→ $30Initiates → BuyGet Alert
09/07/2021TNGXBuy Now
Tango Therapeutics
$1.301207.69%
Chris Shibutani54%
→ $17Initiates → BuyGet Alert
08/12/2021RVMDBuy Now
Revolution Medicines
$38.29-29.49%
Chris Shibutani54%
$49 → $27DowngradeBuy → NeutralGet Alert
07/23/2021MCRBBuy Now
Seres Therapeutics
$0.581112.33%
Chris Shibutani54%
$24 → $7DowngradeNeutral → SellGet Alert
05/18/2021ARNABuy Now
Arena Pharmaceuticals
——
Chris Shibutani54%
→ $90Initiates → BuyGet Alert
05/18/2021BNTXBuy Now
BioNTech
$102.3469.04%
Chris Shibutani54%
→ $173Initiates → NeutralGet Alert
05/18/2021RVMDBuy Now
Revolution Medicines
$38.2927.97%
Chris Shibutani54%
→ $49Initiates → BuyGet Alert
07/14/2020RPTXBuy Now
Repare Therapeutics
$0.93—
Chris Shibutani54%
—Initiates → OutperformGet Alert
02/10/2020ARDXBuy Now
Ardelyx
$4.57—
Chris Shibutani54%
—Initiates → OutperformGet Alert
01/10/2020ADROBuy Now
Aduro Biotech
——
Chris Shibutani54%
—DowngradeOutperform → Market PerformGet Alert
07/15/2019ALKSBuy Now
Alkermes
$27.54-1.96%
Chris Shibutani54%
→ $27UpgradeSell → NeutralGet Alert
05/28/2019BMYBuy Now
Bristol-Myers Squibb
$51.484.9%
Chris Shibutani54%
→ $54Initiates → BuyGet Alert
12/19/2018ALKSBuy Now
Alkermes
$27.54-5.59%
Chris Shibutani54%
$49 → $26DowngradeNeutral → SellGet Alert
01/24/2018PBYIBuy Now
Puma Biotechnology
$2.92—
Chris Shibutani54%
—DowngradeOutperform → Market PerformGet Alert
12/21/2017MRTXBuy Now
Mirati Therapeutics
——
Chris Shibutani54%
—Initiates → OutperformGet Alert
11/07/2017NKTRBuy Now
Nektar Therapeutics
$0.60—
Chris Shibutani54%
—Initiates → OutperformGet Alert
07/18/2017ADROBuy Now
Aduro Biotech
——
Chris Shibutani54%
—Initiates → OutperformGet Alert
05/25/2017PBYIBuy Now
Puma Biotechnology
$2.92—
Chris Shibutani54%
—UpgradeMarket Perform → OutperformGet Alert
05/02/2017RDUSBuy Now
Radius Health
$29.06—
Chris Shibutani54%
—DowngradeOutperform → Market PerformGet Alert
03/24/2017FPRXBuy Now
Five Prime Therapeutics
——
Chris Shibutani54%
—Initiates → OutperformGet Alert
03/24/2017SNDXBuy Now
Syndax Pharmaceuticals
$11.24—
Chris Shibutani54%
—Initiates → OutperformGet Alert
05/06/2016RDUSBuy Now
Radius Health
$29.06—
Chris Shibutani54%
—Assumes → OutperformGet Alert
07/21/2015MCRBBuy Now
Seres Therapeutics
$0.586134.85%
Chris Shibutani54%
→ $36Initiates → NeutralGet Alert
05/05/2015PBYIBuy Now
Puma Biotechnology
$2.92—
Chris Shibutani54%
—DowngradeOutperform → Market PerformGet Alert
07/16/2014RDUSBuy Now
Radius Health
$29.06—
Chris Shibutani54%
—Initiates → OutperformGet Alert
01/05/2014ALKSBuy Now
Alkermes
$27.5434.35%
Chris Shibutani54%
$25 → $37MaintainsNeutralGet Alert
12/19/2012BMYBuy Now
Bristol-Myers Squibb
$51.48-24.24%
Chris Shibutani54%
$40 → $39MaintainsBuyGet Alert
11/13/2012PBYIBuy Now
Puma Biotech
$2.92—
Chris Shibutani54%
—Initiates → OutperformGet Alert
09/11/2012BMYBuy Now
Bristol-Myers Squibb
$51.48-22.3%
Chris Shibutani54%
$38 → $40UpgradeBuy → BuyGet Alert
05/18/2012ALKSBuy Now
Alkermes
$27.54-38.27%
Chris Shibutani54%
$18 → $17MaintainsNeutralGet Alert

Recent Analyst Stock Rating News

The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free